Table 3.
Comparison of the concentrations of the soluble co-stimulatory, co-inhibitory and dual-activity immune checkpoints measured in the plasma of the cohort of early breast cancer patients before and after implementation of neoadjuvant chemotherapy (NAC).
| ICM | Breast Cancer newly diagnosed (n=72) | Post-NAC (n=72) | p value | |
|---|---|---|---|---|
| Median pg/ml (95%CI) | Median pg/ml (95%CI) | |||
| Co-stimulatory | CD27 | 3342.45 | 5351.47 | 0.0001 |
| (2808.61 – 4107.68) | (4678.25 - 5894,.7) | |||
| CD28 | 32914.45 | 44277.76 | 0.0416 | |
| (29326.90 – 42636.04) | (38319.44 – 51220.42) | |||
| CD40 | 1523.32 | 2030.72 | 0.0003 | |
| (1298.16 – 1777.45) | (1792.5 – 2199.04) | |||
| ICOS | 15123.78 | 26586.28 | 0.0002 | |
| (12471.47 – 19942.11) | (20912.88 – 31335.04) | |||
| GITR | 1497.40 | 4035.98 | 0.0001 | |
| (1053.33 – 1969.52) | (3198.29 – 5204.35) | |||
| GITRL | 5886.13 | 5339.99 | 0.8044 | |
| (4959.23 – 6681.22) | (4728.24 – 6121.00) | |||
| CD86 | 11585.17 | 9922,61 | 0,2789 | |
| (9938.61 – 14646.29) | (7890.94 – 11990.77) | |||
| CD80 | 1678.33 | 3048,74 | 0.0001 | |
| (1422.82 – 2039.65) | (2522.82 – 3520.25) | |||
| Co-inhibitory | PD-1 | 12305.41 | 13350.55 | 0.7859 |
| (10260.08 – 15798.61) | (10537.37 – 15491.33) | |||
| PD-L1 | 1647.14 | 4794.97 | 0.0001 | |
| (1269.54 – 2228.88) | (4162.41 – 5731.71) | |||
| CTLA-4 | 1566.38 | 598,20 | 0.0001 | |
| (1314.46 – 1890.81) | (472.91 – 768.78) | |||
| TIM-3 | 3897.66 | 9975.90 | 0.0001 | |
| (3169.51 – 4330.5) | (8793.62 – 10515.70) | |||
| LAG-3 | 131275.90 | 464880.70 | 0.0001 | |
| (106666.3 – 156881.5) | (309218.5 – 580137.6) | |||
| BTLA | 13021.75 | 9987.98 | 0.0367 | |
| (10277.82 – 18548.68) | (8255.35 – 12554.33) | |||
| Dual | TLR-2 | 26831.35 | 33837.86 | 0.0258 |
| (21172.1 – 32396.97) | (28228.61 - 39571,02) | |||
| HVEM | 1865.22 | 4047.29 | 0.0001 | |
| (1671.15 – 2038.38) | (3610.92 – 4445.29) |